Search

Search Constraints

You searched for: Author/Creator Cancel, Mathilde

Search Results

1. Everolimus or sunitinib as first-line treatment of metastatic papillary renal cell carcinoma: A retrospective study of the GETUG group (Groupe d'Etude des Tumeurs Uro-Génitales). (November 2021)

2. Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Issue 5 (May 2022)

3. Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. (July 2022)

4. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma. (November 2022)

5. Cabazitaxel multiple rechallenges in metastatic castration‐resistant prostate cancer. (12th August 2021)

6. Preservation of quality of life in patients with human epidermal growth factor receptor 2–positive metastatic breast cancer treated with tucatinib or placebo when added to trastuzumab and capecitabine (HER2CLIMB trial). (August 2021)

7. Efficacy and safety of regorafenib in patients with metastatic or locally advanced chondrosarcoma: Results of a non-comparative, randomised, double-blind, placebo controlled, multicentre phase II study. (June 2021)

8. Real-life efficacy and predictors of response to immunotherapy in pituitary tumors: a cohort study. Issue 5 (17th October 2022)

9. Patterns of care and outcome of CIC‐rearranged sarcoma patients: A nationwide study of the French sarcoma group. (20th December 2022)